Genetic Testing for COPD

Most COPD is related to smoking or other inhaled exposures. A meaningful minority of people have a genetic contributor: severe AATD. Testing can explain early emphysema, COPD in never smokers, and family risk. Identifying AATD can change monitoring, counseling, and discussions about augmentation therapy in appropriate lung disease settings.

Related condition pages:

• COPD and Alpha-1
• Emphysema and hereditary emphysema
• Symptoms of AATD

Common clinical triggers include:

• Early onset COPD or emphysema
• COPD or emphysema with limited or no smoking history
• Family history of AATD, early emphysema, or unexplained liver disease
• Unexplained chronic liver disease alongside lung findings
• Cascade testing of first degree relatives after a confirmed index case

Broader research questions about autoimmune, cancer, or neurological associations are investigational and are covered on separate hubs with hypothesis labeling.

1. Serum Alpha-1 Antitrypsin level. A low circulating level prompts further workup. Interpret in clinical context because acute inflammation can raise levels.
2. Phenotyping or genotyping. Confirms protein variants or SERPINA1 genotype (for example PIZZ, PIMZ, and other alleles).
3. Clinical correlation. Integrate spirometry, imaging, liver evaluation, family history, and specialist referral as needed.

Laboratory menus and reference ranges vary. Follow your institution's protocols.

Framing the conversation as genetic testing for COPD risk helps patients understand why a blood test or genotype assay is being ordered. Emphasize that:

• A normal result still leaves room for other COPD causes
• An abnormal result is actionable information, not a moral judgment about smoking
• Relatives may benefit from cascade testing after counseling

Patients can also review newly diagnosed resources and the educational self-check.

This page focuses on the COPD genetic testing angle. For a broader clinician oriented overview, see AATD diagnosis and testing. Treatment education lives on medications and treatments.

Point care teams to current specialty resources (for example Alpha-1 Foundation clinical materials and ATS/ERS statements applicable to your practice). The Mark Egly Foundation supports awareness, research funding, and physician networking through Uniting Doctors.

Help fund education and research through ways to give. Read our impact for how donations advance rare disease and Alpha-1 research goals.